OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Psychopharmacology is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	302
Effects of initial nicotine exposure on cognition and nicotine reinforcement among non-smoking young adults with and without attention deficit hyperactivity disorder	224
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	140
Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults	121
Glutamate levels across deep brain structures in patients with a psychotic disorder and its relation to cognitive functioning	94
The chronic effects of a combination of herbal extracts (Euphytose^®) on psychological mood state and response to a laboratory stressor: A randomised, placebo-controlled, double blind study	83
Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a	79
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	69
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	63
Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report	57
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	56
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	47
Psychedelics and the ‘inner healer’: Myth or mechanism?	45
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	45
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	45
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	44
Repurposing psychopharmacology: A two-way street?	43
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	42
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	41
Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment	39
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	38
A framework for assessment of adverse events occurring in psychedelic-assisted therapies	38
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	38
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	37
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	37

The effects of antenatal depression and SSRI exposure on children: A systematic review	36
Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	36
Elevated C-reactive protein among symptomatic youth with bipolar disorder	34
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms	34
What are set and setting: Reducing vagueness to improve research and clinical practice	33
The empathogen 3,4-methylenedioxymethamphetamine, but not methamphetamine, increases feelings of global trust	32
The New Zealand drug harms ranking study: A multi-criteria decision analysis	32
Serotonin release by parachloroamphetamine in rats with high and low sociability: High prefrontal release capacity in sociable females	32